Quantcast
Last updated on April 21, 2014 at 5:21 EDT

Latest Virus-like particle Stories

2010-12-22 07:55:00

QUEBEC CITY, QC, Dec. 22 /PRNewswire/ - Medicago Inc. (TSX: MDG) a biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that the last dose of vaccine has been administered completing the first part of the Company's Phase II human clinical trial with its H5N1 Avian Influenza vaccine ("H5N1 vaccine").  The Company expects to present interim Phase II...

2010-12-22 07:00:00

ROCKVILLE, Md., Dec. 22, 2010 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) and scientists at the University of Massachusetts Medical School, led by Dr. Trudy Morrison, published in the January 2011 issue of The Journal of Virology, a report indicating that a novel virus-like particle (VLP) vaccine candidate against respiratory syncytial virus (RSV) protects mice from a live virus challenge. This vaccine candidate has been created with technology that Novavax has licensed...

2010-12-16 07:00:00

ROCKVILLE, Md., Dec. 16, 2010 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) announced today that the company's Phase I clinical trial to evaluate a new vaccine candidate to prevent respiratory syncytial virus (RSV) infection has been cleared by the U.S. Food and Drug Administration (FDA) and is no longer on clinical hold. In November, the company reported that it had received a question from the FDA regarding chemistry, manufacturing and controls (CMC) that has now been resolved....

2010-12-08 08:14:00

QUEBEC CITY, Dec. 8 /PRNewswire-FirstCall/ - Medicago Inc. (TSX: MDG), a biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced it has engaged Paul Kirkconnell, a seasoned advisor to the pharmaceutical and vaccine industry, as a consultant on business development matters. Paul Kirkconnell, founder of P-A-K Limited, provides biopharmaceutical companies with...

2010-11-29 11:50:00

ROCKVILLE, Md., Nov. 29, 2010 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) a clinical-stage biopharmaceutical company, announced today that Dr. Rahul Singhvi, President and Chief Executive Officer of Novavax, will be presenting at the Piper Jaffray 22nd Annual Healthcare Conference. The presentation will take place on Tuesday, November 30, 2010 at 9:00am local time at The New York Palace Hotel, New York, NY. An audio link to the live presentation can be accessed via the Company...

2010-11-26 07:31:00

QUEBEC CITY, Nov. 26 /PRNewswire/ - Medicago Inc. (TSX: MDG), a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced an extension to its partnering agreement of July 2009 with Genopole(R). Medicago and Genopole(R) will also work towards the creation a laboratory for research on vaccine and antibody targets of interest for France in terms of public health...

2010-11-18 13:13:12

WHAT: In a review article appearing in the New England Journal of Medicine, scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, examine research under way to address the limitations of currently available influenza vaccines and develop more efficient and reliable strategies to make vaccines to protect against seasonal as well as pandemic influenza. Although licensed seasonal flu vaccines safely and effectively protect...

2010-11-12 16:02:00

QUEBEC CITY, Nov. 12 /PRNewswire-FirstCall/ - Medicago Inc. (TSX: MDG), a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles, today announced its operational and financial results for the third quarter ended September 30, 2010. The Company's financial statements and management report are available at www.sedar.com and at www.medicago.com. "There were several key developments...

2010-11-11 07:00:00

ROCKVILLE, Md., Nov. 11, 2010 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) a clinical-stage biopharmaceutical company, announced today that Dr. Rahul Singhvi, President and Chief Executive Officer of Novavax will be presenting at the Lazard 7th Annual Healthcare Conference. The presentation will take place on Tuesday, November 16, 2010 at 1:10pm local time at the St. Regis Hotel, New York, NY. An audio link to the live presentation can be accessed via the Company website at...

2010-11-10 06:00:00

QUEBEC CITY, Nov. 10 /PRNewswire/ - Medicago USA Inc., a wholly owned subsidiary of Medicago Inc. (TSX: MDG) a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), announced today that it has been awarded US$244,279 in funding under the Internal Revenue Service's Qualifying Therapeutic Discovery Project ("QTDP"). This program was created under the Patient Protection and...